Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2013 | 02:40pm CET
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
05:29a GOPRO : renewal and extension of licenses Support
05:28a WAFRAH FOR INDUSTRY AND DEVELOPMENT SJSC : Food products
05:28a NOMISMA S P A : 6 December 2016 - Presentation of the 2016 Report of the Observatory on Italian Agricultural Cooperation
05:26a REGEN : Renovation, Reinforcement and Rebuilding of Shantytowns in Haixin Street
05:26a REGEN : road repair large rural road (under the small line sidewalk) construction
05:26a REGEN : Five detachment of free housing renovation apartment construction
05:26a REGEN : Baibu town 2016 rural highway grade upgrading and dangerous bridge renovation project
05:26a REGEN : Longsha town landscape upgrade project
05:26a REGEN : Wenling Daxi Town Central Primary School Expansion Project
05:26a REGEN : rural highway bridge construction projects
Latest news
Advertisement
Hot News 
16.12%PANDORA MEDIA : Open to Sale -CNBC's Faber
4.77%EXCLUSIVE - TRUMP FINANCIER LADDER CAPITAL EXPLORES SALE : sources
8.45%BERKELEY : says demand down 20 percent after tax hike, Brexit
-2.22%STARBUCKS : CEO steps down to focus on high-end coffee, shares fall
-2.78%BARCLAYS : Deutsche Bank to pay $60 million to settle U.S. gold price-fixing case
Most Read News
10:16p Panasonic in talks to buy ZKW to accelerate push into auto electronics - source
07:27p BAYERISCHE MOTOREN WERKE : BMW seeks to be 'coolest' ride-hailing firm with autonomous car
07:27pDJCheung Kong Bids $5.4 Billion for Duet Group
06:03p SGS : US State of Maine Proposes to Designate 2 Flame Retardants as Priority Chemicals for Reporting
08:28p SHANGHAI DASHENG AGRCLTR FIN TECH : Monthly Returns-Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2016
Most recommended articles
12/02 Platts considers first addition to Brent basket since 2007
11/30DJCash Crunch Looms Over India's Growth Spurt
11/27DJOil Industry Anticipates 'Peak Demand' Day of Reckoning
11:15pDJBANCA MONTE DEI PASCHI DI SIENA : Italy Rejects Renzi, Buoys Populists
11:12p HON HAI PRECISION INDUSTRY : Sharp CEO Tai says to step down once stock returns to TSE first section